drugset

drugset / Trial / NCT00014729

Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa

NCT00014729 ↗

Phase 1 Completed 20 enrolled University of North Carolina

Treatment

Summary

OBJECTIVES: I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.

Timeline

Start: 2000-10
Primary completion: —
Completion: 2002-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isotretinoin	Other / unclassified	—	Oral

Indications